Orchestra BioMed: Partnering with Medtronic to Tackle Global Hypertension | NYSE Interview

18 Visioni

  • Grazie! Condividilo con i tuoi amici!

    Non hai gradito questo video. Grazie per il feedback!

admin
Published
#Hypertension #MedTech #medicaldevicesale

Forward Looking Statements: http://bit.ly/4nHgE6t

https://www.orchestrabiomed.com At the New York Stock Exchange, Jane King interviews David Hochman, Chairman & CEO of Orchestra BioMed (NASDAQ: OBIO), a biomedical innovation company revolutionizing the treatment of high-impact conditions like hypertension and artery disease.

???? Key Highlights
– Strategic partnerships with Medtronic & Terumo
– Royalty-based business model inspired by pharma
– AVIM Therapy for hypertension: a pacemaker-integrated solution
– Global pivotal trials underway with breakthrough FDA designation
– Upcoming coronary trial for Virtue® balloon-based artery therapy
– Small, elite team with decades of medical device experience
– Long-term vision: scale innovation through capital-efficient partnerships

???? Quote from David Hochman:
"We're applying a pharma-style risk-reward model to the medical device space—leveraging global partners like Medtronic to help bring groundbreaking therapies to millions of patients."

???? Learn more: https://orchestrabiomed.com

???? Filmed at: New York Stock Exchange
???? Ticker: NASDAQ: OBIO

#Hypertension #MedTech #MedicalDevices #NYSE #JaneKing #OrchestraBioMed #Medtronic #AVIM #RoyaltyModel #HealthcareInnovation #VentureCapital #Atherosclerosis #Cardiology #DavidHochman #VirtueBalloon
Categoria
Cardiology
Commenta per primo questo video.

Prossimo